Compare GRWG & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRWG | CYPH |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | 253 | 6 |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 73.4M |
| IPO Year | 2015 | N/A |
| Metric | GRWG | CYPH |
|---|---|---|
| Price | $1.45 | $0.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 212.7K | ★ 1.6M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $193,365,479.00 | N/A |
| Revenue This Year | $5.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.51 | N/A |
| 52 Week Low | $1.01 | $0.49 |
| 52 Week High | $2.40 | $3.70 |
| Indicator | GRWG | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 38.88 |
| Support Level | $1.46 | $0.58 |
| Resistance Level | $1.60 | $0.79 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 67.32 | 8.51 |
GrowGeneration Corp owns and operates specialty retail stores focused on hydroponic and organic gardening. The company markets and distributes nutrients, growing media, indoor and greenhouse lighting, ventilation systems, and related accessories. It operates through two reportable segments: Cultivation and Gardening, which includes its hydroponic and organic gardening business, and Storage Solutions, which includes its benching, racking, and storage solutions operations. The company generates revenue mainly from the sale of proprietary and non-proprietary products through retail stores, e-commerce platforms, wholesale distribution, and commercial sales, along with the sale and installation of commercial fixtures.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.